60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 14, 2024 14:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
October 03, 2024 09:02 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
August 14, 2024 11:01 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
July 25, 2024 09:02 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
January 30, 2024 09:00 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research
TTCR Improvement Tafenoquine v Placebo
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
October 12, 2023 16:16 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma Suspends Phase IIB COVID Study, Pivots to Commercialization of Treatments for Malaria and Tick-borne Illness
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
July 31, 2023 07:59 ET | Sixty Degrees Pharmaceuticals
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering
July 14, 2023 12:39 ET | Sixty Degrees Pharmaceuticals
WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious...
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
July 12, 2023 12:29 ET | Sixty Degrees Pharmaceuticals
WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious...